Alterity Therapeutics Limited (ATHE) Stock Ticker
Market factors today
Unlock the full ATHE picture
About Alterity Therapeutics Limited
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
ATHE stock facts
| Ticker symbol | ATHE |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $62.2M |
| CEO | David A. Stamler |
| Employees | 11 |
| Headquarters | Melbourne, VIC, AU |
| IPO date | 2003-09-29 |
| Website | alteritytherapeutics.com |
What you can see for ATHE on Tickr
Live ATHE price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ATHE report.
Rankings
FAQ
What is the ticker symbol for Alterity Therapeutics Limited?
The ticker symbol for Alterity Therapeutics Limited is ATHE, listed on the NASDAQ Capital Market.
What is ATHE?
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that…